S9 Ep42: Halmos Highlights Evaluation of the EGFR Inhibitor BDTX-1535 in NSCLC
OncLive® On Air - Un pódcast de OncLive® On Air
Dr Halmos discusses the ongoing investigation of the potent, selective, and irreversible EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer.
